Objective: The aim of this study was to identify clinical and demographic characteristics that moderate response to treatment with fesoterodine among women with a diagnosis of urgency-predominant urinary incontinence.
U rinary incontinence is common among women in the United
States with an overall prevalence of 10% to 15% 1 and as high as 77% in some populations such as elderly patients or those with cognitive dysfunction. 2 While urinary incontinence is not generally associated with an increased mortality, 3 it can have significant adverse impact on quality of life, sexual function, medical morbidity, and caregiver burden. A simple 3-item self-administered questionnaire, the 3-item Incontinence Questionnaire (3IQ), has been demonstrated to be an effective measure both to identify women with urgency-predominant urinary incontinence (UUI) and to facilitate initiation of pharmacologic treatment without further clinical evaluation. 4 This study showed that among ambulatory women with UUI diagnosed with the 3IQ, there was a significant reduction in urinary incontinence episodes at 12 weeks with pharmacological treatment compared with a placebocontrolled group, without an increase in adverse events. 4 There is a lack of knowledge about the use of antimuscarinics in the general population. Many clinical trials have demonstrated the efficacy of antimuscarinic medications to treat UUI, yet there are limited data on effectiveness in different patient populations. Clinical trials for pharmacological therapy typically include subgroup analyses stratified by age and sex, but generally do not provide comprehensive information about the effect of additional demographic and clinical characteristics. While studies of the general population may provide information with better clinical applicability, the heterogeneity of the sample makes analysis difficult. We therefore felt that a secondary analysis of a clinical trial with specific inclusion and exclusion criteria would provide valuable information.
The goal of this study was to identify clinical and demographic characteristics that moderate pharmacologic treatment response among women with a diagnosis of UUI identified by the 3IQ. This may facilitate predicting good and/or poor response to streamlined pharmacological therapy initiation with the 3IQ and help to inform patients' expectation of treatment. The investigation involves a secondary analysis of a previously published study.
MATERIALS AND METHODS

Participants
A multicenter, double-blind, 12-week randomized trial of pharmacological therapy and placebo control for urgencypredominant incontinence in women diagnosed by the simple 3IQ was previously performed. 4 Participants were communitydwelling, ambulatory women at least 18 years old recruited at 13 clinical sites in the United States. Complete study methods and results were previously published. 4 In brief, the study population included women with urgency or mixed urgency predominant urinary incontinence with at least 3 episodes of urgency urinary incontinence on a 3-day bladder diary. Women were excluded if they self-reported complex medical histories that would require a specialist evaluation for incontinence before initiating pharmacological therapy. Participants were assigned randomly to fesoterodine 4 to 8 mg daily or identical-appearing placebo. All participants were asked to not initiate other pharmacologic incontinence treatments and pelvic floor or bladder physical therapy for the 12-week trial period. According to previously established protocols for participant-directed dosing, participants were started initially on fesoterodine 4 mg and offered the option of increasing their dose to fesoterodine 8 mg at 2, 4, and 8 weeks with maximum of 8 mg or minimum of 4 mg daily.
Measures
At the initial visit, participants completed the 3IQ and questionnaires on demographic characteristics (eg, age, race or ethnicity, education), habits (eg, smoking, alcohol consumption), medication use, and reproductive (eg, parity, menopause status), medical (eg, diabetes, hypertension, stroke, chronic liver disease), surgical (eg, previous hysterectomy), and incontinence (eg, age of onset of incontinence, and duration (in years) of incontinence) histories. Physical examination included body mass index (BMI) measurement, a thorough pelvic examination, basic neurologic examination, and cough stress test, and measurement of postvoid residual volume and urine analysis were performed. 4 At baseline and 12 weeks, women also completed a validated 3-day voiding diary including number of voids, incontinence episode by type (urgency, mixed, other), and sensation of urgency (rated as none, mild, moderate, or severe). Participants completed the Patient Perception of Bladder Condition, a validated single-item global measure of patients' subjective impression of their current urinary problems. 5 Participants also completed the Overactive Bladder Questionnaire, a 33-item, condition-specific measure designed to assess the impact of overactive bladder questionnaire symptoms. 6 
Statistical Analysis
Baseline characteristics of participants in each treatment group and of responders and nonresponders were compared using χ 2 or Kruskal-Wallis tests. Baseline urinary incontinence episodes were compared using analysis of variance models. At 12 weeks, a therapeutic responder was defined by reduction of 50% or greater in incontinence-episode frequency (all types) from baseline, a clinically meaningful threshold for incontinence improvement. 7, 8 Conversely, a nonresponder was defined by less than 50% reduction in incontinence-episode frequency from baseline. Moderation by clinical and demographic characteristic was assessed by testing interaction terms between each clinical characteristic and intervention in logit models of responders adjusted for clinical site. P < 0.05 was considered significant. Analyses were performed in SAS 9.4 (SAS Institute, Cary, NC).
RESULTS
A total of 645 participants were randomly assigned to fesoterodine therapy (n = 322) or placebo (n = 323). Follow-up at 12 weeks was similar between groups (fesoterodine n = 271 [82%] and control n = 278 [86%]). At baseline, among the 549 participants with 12-week follow-up data, mean age was 56 (SD, 14) years, 66% were of white race, and women reported 3.9 (SD, 3.0) urgency incontinence episodes per day (Table 1) . Baseline characteristics did not differ significantly between the 2 treatment groups, nor did they differ between responders and nonresponders (data not shown). There were also no differences in baseline incontinence episode frequency between responders and nonresponders when stratified by age, BMI, race/ethnicity, education, relationship status, employment, alcohol use, smoking status, menopausal status, gravidity, or parity (data not shown).
Response to pharmacological treatment at 12 weeks was moderated by several clinical and demographic characteristics including age, marital status, education, parity, and incontinence type ( Table 2 ). There was an increase in the proportion of responders to fesoterodine with increasing age (P = 0.04). The treatment effect was nonsignificant in those younger than 45 years, but increasingly stronger in those older than 45 years. Among participants aged 18 to 28 years treated with fesoterodine, 48% were therapeutic responders compared with 76% of women 75 years or older. An inverse trend was seen among women in the placebo group, with more younger women responding to placebo treatment (60%) than older women (31%). Similarly, an increase in responders to fesoterodine among participants who were married or living as married (74%) compared with single women (68%; P = 0.03) and an inverse relationship in the placebo arm, with response rate among married women lower than that among single women (44% vs. 57%, respectively, P = 0.03), were noted. Education had a complex relationship with treatment response but did demonstrate significant effect modification (P = 0.03). Increasing parity was associated with higher responder rate (P = 0.04). Finally, urgency urinary incontinence type modified treatment response, with 74% of women with pure UUI achieving therapeutic response compared with 68% with urgencypredominant mixed urinary incontinence (P = 0.04). We observed no modification of treatment response by race/ ethnicity, BMI, employment status, alcohol or tobacco use, or menopausal status.
DISCUSSION
In this secondary analysis of a previously published randomized controlled trial of pharmacological therapy for UUI, age, marital status, and parity were all significant modifiers that potentiate the effects of treatment with fesoterodine. To our knowledge, this is the first analysis of data from randomized trial that provides data allowing a comprehensive evaluation of clinical and demographic predictors of treatment response to pharmacologic treatment of UUI.
Prior pharmacokinetic studies of antimuscarinic drugs for UUI have demonstrated that increasing age is often associated with more frequent and significant adverse effects including dry mouth, blurry vision, sedation, and confusion.
9 Phases 2 and 3 placebo-controlled efficacy and safety studies of fesoterodine showed the incidence of treatment-associated adverse events, including dry mouth, constipation, dyspepsia, increase in residual urine, dizziness (at 8 mg only), and urinary tract infection, was higher in women 75 years or older compared with younger women. [10] [11] [12] [13] The active metabolite of fesoterodine, 5-hydroxymethyl tolterodine, is known to undergo extensive metabolism and clearance by the liver. In elderly patients, many drugs demonstrate an exaggerated response secondary to decreased drug metabolism and clearance.
14 Perhaps this pharmacokinetic difference among older participants explains the observed effect modification in this study.
There are conflicting data on the change in pharmacologic efficacy with increased age. Phases 2 and 3 placebocontrolled efficacy and safety studies of fesoterodine showed Continued next page no overall differences in efficacy between younger participants compared with those older than 65 years. However, in a post hoc analysis of data from a fixed-dose trial of fesoterodine stratified by age, fesoterodine 4 and 8 mg improved symptoms significantly more than placebo in participants younger than 65 years and in a group aged 65 to 74 years; only fesoterodine 8 mg was effective in participants 75 years or older. 13 There has been 1 randomized controlled trial of a drug from the same class that looked specifically at the geriatric population observing that overall efficacy in an older population was greater than efficacy noted in prior studies of the general population. 15 There are limited data reporting on other demographic characteristics and response to treatment by antimuscarinic medications. In phase 1 placebo-controlled trials, there was no difference in the pharmacokinetics of fesoterodine between different racial groups, suggesting similar levels of efficacy. Studies of other antimuscarinic agents including solifenacin 16, 17 and tolterodine tartrate, 18 however, concluded that the number of subjects of different races studied in phase 1 trials was not adequate to make any conclusions on the effect of race on the pharmacokinetics of these antimuscarinic drugs. Prior efficacy studies of fesoterodine have not commented specifically on differences in efficacy between racial groups, and the studies likely have limited power due to sample size.
Increased parity was also associated with greater likelihood of treatment response, which may suggest that there is some physiologic change brought on by pregnancy/delivery that affects the efficacy of therapy. Perhaps the pathophysiologic mechanism of UUI is different among parous women compared with nulliparous women. We are unclear why there was a difference in treatment response based on marital status, and marital status has not been studied in similar drug trials. It is possible that marital status was a marker for other unmeasured socioeconomic (or other) characteristics that modified treatment response, or this may be a spurious finding.
While age and marital status were associated with increased efficacy in the treatment group, we noted an inverse relationship in the placebo group with age and marital status associated with decreased response. Studies of drugs in other fields of medicine including depression, 19 epilepsy, 20 and migraines 21 have noted significantly increased placebo response among younger respondents and have suggested that the response to placebo may be dependent on the age of patients. Effect modification by the type of incontinence is logical because fesoterodine is a drug that specifically treats UUI. A higher percentage of women with pure urgency incontinence compared with mixed urgency incontinence achieved a therapeutic treatment response.
In addition to understanding the relationship between demographic characteristics and treatment efficacy, it is also important to understand which patients may be at risk of treatment failure. Data from this study suggest that younger patients and nulliparous patients may benefit from evaluation by a specialist, given the lower frequency of therapeutic responders. Clinical and demographic characteristics associated with pharmacological treatment failure may help predict which patients warrant more thorough evaluation and streamline diagnostic testing and treatment choice.
The major strengths of this study include that the data were collected from a multicenter, randomized, placebo-controlled trial with comprehensive evaluation of demographic and clinical characteristics. However, we acknowledge several limitations. This study involves a secondary analysis, which the primary study was not powered to assess, which may explain the lack of associations with several demographic strengths. This study looked specifically at UUI and excluded patients with stress only or stresspredominant mixed incontinence or those with urinary urgency in the absence of incontinence. This study also excluded participants with major comorbidities that might warrant further evaluation by a specialist prior to initiation of pharmacologic therapy. Therefore, our population may not be entirely generalizable. Finally, this study involved the use of 1 antimuscarinic drug, and there are several similar drugs that work through similar mechanism of action. It would be reasonable to assume that the effect modification would be similar for drugs in the same general class, but further studies are clearly needed before making definitive statements.
In conclusion, this study provides evidence to identify certain subpopulations that may be more responsive to treatment with antimuscarinic therapy, in particular women who are older, parous, or married or report urgency-only incontinence. By identifying demographic characteristics associated with a better clinical response, primary care providers can better select those patients who may benefit from initial treatment. 
